SCHEMBL6469271

SCHEMBL6469271

CCCCN(CC)c1cnc(C(N)=O)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 2/20 0.41
HCAR3 P49019 2/20 0.39
KDM4E B2RXH2 2/20 0.37
TSHR P16473 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
ALOX15 P16050 1/20 0.37
NFKB1 P19838 1/20 0.37
THPO P40225 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
KMT2A Q03164 1/20 0.37
HIF1A Q16665 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5042470 0.84 HCAR3 (0.46) SIRT6HCAR3KDM4ETSHRTDP1
SCHEMBL5133491 0.78 HCAR3 (0.43) SIRT6HCAR3KDM4ETSHRTDP1
SCHEMBL5133216 0.77 NNMT (0.41) HCAR3KDM4EMEN1ALDH1A1CYP1A2
SCHEMBL30482977 0.76 SIRT6 (0.46) SIRT6HCAR3KDM4ETSHRTDP1
SCHEMBL6469274 0.76 MAPT (0.36) HCAR3KDM4EMEN1ALDH1A1LMNA
SCHEMBL5134193 0.76 TSHR (0.44) SIRT6HCAR3KDM4ETSHRTDP1
SCHEMBL5133377 0.75 S1PR1 (0.46) HCAR3CRHR1
SCHEMBL30874243 0.72 SIRT6 (0.52) SIRT6HCAR3KDM4ETSHRALDH1A1
SCHEMBL2222631 0.72 SIRT6 (0.52) SIRT6HCAR3KDM4ETSHRALDH1A1
SCHEMBL6470817 0.72 CNR1 (0.35) HCAR3KDM4ETSHRMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA SIRT6 750/4885HCAR3 748/4885KDM4E 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.